Focus on paroxetine

被引:19
作者
Green, B [1 ]
机构
[1] Royal Liverpool Univ Hosp, Dept Psychiat, Liverpool L69 3GA, Merseyside, England
[2] N Cheshire Hosp NHS Trust, Halton, Cheshire, England
关键词
anxiety disorders; depressive disorders; obsessive compulsive disorder; paroxetine; post-traumatic stress disorder; SSRI antidepressant;
D O I
10.1185/030079902125001353
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This review of paroxetine is based on Medline and PsycLit searches and a manual search of the available research literature. It aims to cover the pharmacology of this frequently prescribed SSRI antidepressant in terms of its indications, efficacy and adverse effects. Overall, paroxetine is a well-tolerated and safe first-line SSRI antidepressant with anxiolytic qualities. It has been found useful in depression, anxiety and other conditions such as obsessive compulsive disorder and post-traumatic stress disorder. The antidepressant has some advantages over earlier tricyclic medication in terms of a lack of cardiovascular side-effects and relative safety in overdose. Cessation of use, however, is associated with withdrawal or discontinuation symptoms and patients should be counselled as to how these might be avoided. A 3- or 4-week graded withdrawal regimen, perhaps with concomitant fluoxetine to cover serotonergic discontinuation symptoms, may be advisable.
引用
收藏
页码:13 / 21
页数:9
相关论文
共 71 条
[1]   Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation [J].
Abdel-Hamid, IA ;
El Naggar, EA ;
El Gilany, AH .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2001, 13 (01) :41-45
[2]   Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder [J].
Agid, O ;
Shalev, AY ;
Lerer, B .
JOURNAL OF CLINICAL PSYCHIATRY, 2001, 62 (03) :169-173
[3]  
ASHTON H, 1987, BRAIN SYSTEMS DISORD
[4]   Akathisia: A review and case report following paroxetine treatment [J].
Baldassano, CF ;
Truman, CJ ;
Nierenberg, A ;
Ghaemi, SN ;
Sachs, GS .
COMPREHENSIVE PSYCHIATRY, 1996, 37 (02) :122-124
[5]   Paroxetine in social phobia/social anxiety disorder -: Randomised, double-blind, placebo-controlled study [J].
Baldwin, D ;
Bobes, J ;
Stein, DJ ;
Scharwächter, I ;
Faure, M .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 175 :120-126
[6]   Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder [J].
Ballenger, JC ;
Wheadon, DE ;
Steiner, M ;
Bushnell, W ;
Gergel, IP .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (01) :36-42
[7]  
BARR LC, 1994, AM J PSYCHIAT, V151, P289
[8]  
Benmansour S, 1999, J NEUROSCI, V19, P10494
[9]   COST-ANALYSIS OF PAROXETINE VERSUS IMIPRAMINE IN MAJOR DEPRESSION [J].
BENTKOVER, JD ;
FEIGHNER, JP .
PHARMACOECONOMICS, 1995, 8 (03) :223-232
[10]   Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial [J].
Bordet, R ;
Thomas, P ;
Dupuis, B .
AMERICAN JOURNAL OF PSYCHIATRY, 1998, 155 (10) :1346-1351